Canopy Growth's Business Is Improving. So Why Isn't the Stock Performing Better?

Canopy Growth reported fiscal Q1 2027 net revenue of C$81.2 million (US$58.6 million), up 13% year over year, while net losses fell 68% and adjusted EBITDA losses declined 59%. Despite improving operations, the stock remains below US$1 and is down 33% over 12 months as federal U.S. cannabis legalization progress has stalled. Dilution remains a major risk: shares outstanding rose from 239.9 million to 423 million over the past year, and an authorized US$200 million ATM program could substantially dilute investors relative to its US$394 million market capitalization.

Analysis

WEED’s operating improvement is unlikely to rerate the equity while financing remains equity-dependent: each incremental dollar raised at a sub-$1 share price transfers a disproportionate share of any future turnaround to new holders. The key issue is not near-term EBITDA-loss reduction but whether operating cash flow can fund working capital and interest without further ATM issuance; absent that proof, the equity should trade as a financing option rather than on a normalized revenue multiple.

The more relevant U.S. regulatory read-through is to profitable, domestically scaled operators rather than Canadian LPs. A federal reform that lowers tax friction or improves banking/access to capital would disproportionately expand free-cash-flow conversion for U.S. operators such as Green Thumb (GTBIF), Curaleaf (CURLF), Trulieve (TCNNF), and Verano (VRNOF), whereas WEED still faces execution, corporate-structure, and potential cross-border constraints. This creates a cleaner 6-18 month relative-value expression than a directional cannabis bet.

Near term, WEED can still squeeze on regulatory headlines because its low nominal price and retail ownership amplify flow sensitivity. But a headline-driven rally without a financing update or sustained positive operating cash flow should be sold: the market will likely capitalize the remaining authorized equity capacity as an overhang. Falsification would be two consecutive quarters of positive operating cash flow with no material share-count increase, or a binding federal rule that directly enables its U.S. assets to consolidate economics and access institutional capital.

Key Decisions for Investors

• Maintain an avoid/underweight on WEED over the next 1-3 months; do not treat improving adjusted EBITDA as investable until cash flow and diluted share-count data confirm self-funded operations. Reassess if quarterly share growth falls below 2% and operating cash flow turns sustainably positive.
• For a 6-18 month regulatory normalization thesis, prefer a basket long GTBIF, TCNNF, and VRNOF versus short WEED in equal dollar amounts. The pair isolates U.S. cash-flow and tax-regulatory upside from Canadian LP dilution risk; exit if federal reform stalls or the relative basket underperforms by 15%.
• Use any WEED rally driven solely by legalization headlines as an entry point for a tactical short or put structure, subject to borrow availability. Target a 20-30% downside over 1-3 months; risk-manage above the post-headline high because retail-driven short squeezes can be abrupt.
• Set an event alert around WEED’s next filing for ATM proceeds, weighted-average issuance price, cash burn, and going-concern language. A material draw on remaining issuance capacity at depressed prices would reinforce the short thesis; no draw combined with improved cash conversion would invalidate it.